FY2024 Earnings Estimate for Curis, Inc. Issued By Cantor Fitzgerald (NASDAQ:CRIS)

Curis, Inc. (NASDAQ:CRIS) – Investment analysts at Cantor Fitzgerald issued their FY2024 earnings per share estimates for Curis in a report issued on Wednesday, May 8th. Cantor Fitzgerald analyst L. Watsek anticipates that the biotechnology company will post earnings of ($3.47) per share for the year. The consensus estimate for Curis’ current full-year earnings is ($5.40) per share.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $26.00 target price on shares of Curis in a research report on Wednesday, May 8th.

Curis Stock Performance

NASDAQ:CRIS opened at $15.72 on Monday. The stock’s 50-day simple moving average is $13.31 and its 200 day simple moving average is $11.26. The company has a market cap of $92.65 million, a P/E ratio of -1.83 and a beta of 3.59. Curis has a 52-week low of $3.80 and a 52-week high of $19.60.

Curis (NASDAQ:CRIS) last released its earnings results on Tuesday, May 7th. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.94) by ($0.11). The company had revenue of $2.09 million during the quarter, compared to analyst estimates of $2.31 million. Curis had a negative net margin of 486.45% and a negative return on equity of 224.75%. During the same period in the prior year, the firm posted ($2.40) EPS.

Hedge Funds Weigh In On Curis

A number of institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its position in Curis by 4.8% during the first quarter. Vanguard Group Inc. now owns 218,573 shares of the biotechnology company’s stock worth $2,376,000 after buying an additional 10,097 shares during the last quarter. Focused Wealth Management Inc increased its position in Curis by 79.2% during the first quarter. Focused Wealth Management Inc now owns 33,158 shares of the biotechnology company’s stock worth $360,000 after buying an additional 14,656 shares during the last quarter. Franklin Street Advisors Inc. NC acquired a new position in Curis during the first quarter worth approximately $219,000. Finally, a16z Perennial Management L.P. acquired a new position in shares of Curis in the fourth quarter valued at approximately $85,000. Institutional investors and hedge funds own 29.97% of the company’s stock.

Curis Company Profile

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.